Researchers at the Mayo Clinic have discovered genetic variations that may help predict breast cancer risk in women receiving tamoxifen and raloxifene, two estrogen receptor modulator drugs. By analyzing the DNA of study participants, two genetic variations, or single nucleotide polymorphisms (SNPs), associated with breast cancer risk, were identified. According to Dr. James Ingle, oncologist at the Mayo clinic, the findings are significant, as they provide "clear direction as to which women are likely and which are unlikely to benefit from tamoxifen or raloxifene."
To read more about this study, click here
Study mentioned: Ingle JN et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: Individualized breast cancer prevention. Cancer Discov. 2013 Jun 13 [Epub ahead of print]. PMID: 23764426
No comments:
Post a Comment